Metabolic dysfunction–associated steatotic liver disease

Metabolic dysfunction–associated steatotic liver disease

NASH: Madrigal Files Resmetirom In EU While US Action Date Closes In

Resmetirom, which could become the first approved treatment for non-alcoholic steatohepatitis, is among 11 new drugs that the European Medicines Agency has started to review for potential EU approval. Meanwhile, a decision on whether to approve the drug is pending in the US.

Metabolic dysfunction–associated steatotic liver disease, also known as NASH, is a serious condition characterized by the accumulation of fat in the liver. With the potential approval of Resmetirom, there is hope for patients suffering from this debilitating disease.

Stay updated on the latest developments in the treatment of metabolic dysfunction–associated steatotic liver disease by following our news aggregator website.